Vontobel Holding Ltd. Makes New Investment in BriaCell Therapeutics Corp. (NASDAQ:BCTX)

Vontobel Holding Ltd. purchased a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned about 0.44% of BriaCell Therapeutics as of its most recent SEC filing.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.

BriaCell Therapeutics Price Performance

Shares of BCTX opened at $0.92 on Thursday. BriaCell Therapeutics Corp. has a 12 month low of $0.46 and a 12 month high of $5.97. The stock has a market cap of $16.82 million, a PE ratio of -0.74 and a beta of 1.34. The stock’s 50-day moving average is $0.77 and its two-hundred day moving average is $1.21.

BriaCell Therapeutics Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.